Clinical Trials
4 trialsNCT05663866 2026-06-02
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT04270409 2025-12-12
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
Phase 3 Active not recruiting
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed